Progress and Pitfalls in the Quest for Effective SARS-CoV-2 (COVID-19) Vaccines
Katie L Flanagan, Emma Best, Nigel W Crawford, Michelle Giles, Archana Koirala, Kristine Macartney, Fiona Russell, Benjamin W Teh, Sophie CH Wen
FRONTIERS IN IMMUNOLOGY | FRONTIERS MEDIA SA | Published : 2020
There are currently around 200 SARS-CoV-2 candidate vaccines in preclinical and clinical trials throughout the world. The various candidates employ a range of vaccine strategies including some novel approaches. Currently, the goal is to prove that they are safe and immunogenic in humans (phase 1/2 studies) with several now advancing into phase 2 and 3 trials to demonstrate efficacy and gather comprehensive data on safety. It is highly likely that many vaccines will be shown to stimulate antibody and T cell responses in healthy individuals and have an acceptable safety profile, but the key will be to confirm that they protect against COVID-19. There is much hope that SARS-CoV-2 vaccines will ..View full abstract
This project was supported by the Australasian Society for Infectious Diseases (ASID) Vaccination Special Interest group (VACSIG).